Status:
COMPLETED
Adrenomedullin Upregulation in Apical Periodontitis
Lead Sponsor:
Istanbul Medipol University Hospital
Conditions:
Periapical Periodontitis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of the present study was to investigate the relationship between Apical periodontitis (AP) severity and inflammatory markers (IL-12, TNF-alpha), and Mid-Regional Pro Adrenomedullin (MR-proADM)...
Detailed Description
Bone destruction in apical periodontitis (AP) depends on the microorganisms' efficiency to breach the host-epithelial barrier and various antimicrobial peptides. Mid-regional pro adrenomedullin (MR-pr...
Eligibility Criteria
Inclusion
- Must be systemically healthy Patients with only apical periodontitis (for AP group) Patients with only chronic periodontitis (for CP group) Orally healthy patients
Exclusion
- any local or systemic inflammatory disease connective tissue diseases like systemic lupus erythematosus (SLE) cardiovascular disease inflammatory and rheumatic disease diabetes rheumatoid arthritis, or Behcet's disease granulomatous diseases like sarcoidosis inflammatory intestinal diseases like ulcerative colitis and Crohn's autoimmune intestinal diseases like celiac thyroid diseases like Hashimoto and Graves patients who had taken antibiotics and/or anti-inflammatory drugs within the last 6 months those with pregnancy or lactation
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT05297747
Start Date
June 1 2020
End Date
October 30 2021
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medipol University, Faculty of Dentistry
Istanbul, Esenler, Turkey (Türkiye)